PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21839399-2	2011	OBJECTIVE: A decision analytic (DA) model was developed to evaluate the cost-effectiveness analysis (CEA) of linezolid, daptomycin, and vancomycin in MRSA cSSSI.	Linezolid	109-118	solute carrier family 9 member A6	Homo sapiens	150-160
21839399-13	2011	CONCLUSION: Linezolid and daptomycin are potentially cost-effective based on the assumptions of the DA model; however, linezolid appears to be more cost-effective compared to daptomycin and vancomycin for MRSA cSSSIs.	Linezolid	119-128	solute carrier family 9 member A6	Homo sapiens	205-209
21624345-1	2011	Linezolid, an oxazolidinone class derivative is a reversible and nonselective inhibitor of monoamine oxidase (MAO), predominantly for MAO-A type.	Linezolid	0-9	monoamine oxidase A	Mus musculus	134-139
21682676-3	2011	The main regime of antibiotic treatment recommended for MRSA pneumonia is either vancomycin or linezolid.	Linezolid	95-104	solute carrier family 9 member A6	Homo sapiens	56-60
21357301-6	2011	The PPK analysis revealed that renal function and severe liver cirrhosis (Child Pugh grade C) significantly affect the pharmacokinetics of linezolid according to the equation clearance (liter/h)=2.85x(creatinine clearance/60.9)0.618x0.472CIR (CIR indicates cirrhosis status; 0 for noncirrhosis, 1 for cirrhosis patients).	Linezolid	139-148	kallikrein B1	Homo sapiens	4-7
21357301-6	2011	The PPK analysis revealed that renal function and severe liver cirrhosis (Child Pugh grade C) significantly affect the pharmacokinetics of linezolid according to the equation clearance (liter/h)=2.85x(creatinine clearance/60.9)0.618x0.472CIR (CIR indicates cirrhosis status; 0 for noncirrhosis, 1 for cirrhosis patients).	Linezolid	139-148	corepressor interacting with RBPJ, CIR1	Homo sapiens	238-241
21357301-6	2011	The PPK analysis revealed that renal function and severe liver cirrhosis (Child Pugh grade C) significantly affect the pharmacokinetics of linezolid according to the equation clearance (liter/h)=2.85x(creatinine clearance/60.9)0.618x0.472CIR (CIR indicates cirrhosis status; 0 for noncirrhosis, 1 for cirrhosis patients).	Linezolid	139-148	corepressor interacting with RBPJ, CIR1	Homo sapiens	243-246
21685529-10	2011	In cases of empirical administration, it is necessary to use antibiotics with high level of activity against pneumonia agents - carbapenems, and in case of high probability of MRSA - it is better to use linezolid or vancomicin.	Linezolid	203-212	solute carrier family 9 member A6	Homo sapiens	176-180
21296123-4	2011	Expression of the hemoglobin beta chain complex (Hbb), aminolevulinic acid synthase 2 (Alas2), and cell division cycle 25 homolog B (Cdc25b) genes changed as a result of anemia induced by the myelosuppressive agents linezolid, cisplatin, and carboplatin, suggesting that these genes may be suitable biomarkers.	Linezolid	216-225	cell division cycle 25B	Rattus norvegicus	133-139
21497067-0	2011	Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).	Linezolid	60-69	mitochondrial antiviral signaling protein	Homo sapiens	141-146
21497067-3	2011	The objective of this study was to evaluate the activity of telavancin, vancomycin and linezolid against hVISA clinical strains.	Linezolid	87-96	mitochondrial antiviral signaling protein	Homo sapiens	105-110
21282430-0	2011	Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.	Linezolid	57-66	GLI family zinc finger 2	Homo sapiens	177-182
21282430-7	2011	In the THP-1 cell line model, both dicloxacillin (DCX) and linezolid (LZD) reduced the intracellular inocula of bacteria of both phenotypes by approximately 1 to 1.5 log(10) in vitro, while DCX was considerably more effective against extracellular bacteria.	Linezolid	59-68	GLI family zinc finger 2	Homo sapiens	7-12
21282430-7	2011	In the THP-1 cell line model, both dicloxacillin (DCX) and linezolid (LZD) reduced the intracellular inocula of bacteria of both phenotypes by approximately 1 to 1.5 log(10) in vitro, while DCX was considerably more effective against extracellular bacteria.	Linezolid	70-73	GLI family zinc finger 2	Homo sapiens	7-12
21624345-4	2011	Hence, the objective of this study was to evaluate the anti-depressant-like effect of linezolid, a MAO-A inhibitor in the animal models of depression.	Linezolid	86-95	monoamine oxidase A	Mus musculus	99-104
21412669-16	2011	CONCLUSIONS: Linezolid was mainly indicated in post-neurosurgical EVD-associated infections due to coagulase-negative Staphylococcus spp.	Linezolid	13-22	histocompatibility minor 13	Homo sapiens	133-136
21940270-9	2011	Only linezolid had high activity against both the VanA and the VanB phenotypes.	Linezolid	5-14	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	50-54
21940270-9	2011	Only linezolid had high activity against both the VanA and the VanB phenotypes.	Linezolid	5-14	D-alanine--D-lactate ligase	Enterococcus faecium	63-67
22830148-12	2011	Linezolid was used for MRSA.	Linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	23-27
22830148-19	2011	MRSA was treated successfully with Linezolid.	Linezolid	35-44	solute carrier family 9 member A6	Homo sapiens	0-4
20429820-12	2010	CONCLUSION: The results of this meta-analysis suggest higher success rates for linezolid and the new glycopeptides (dalbavancin and telavancin) in MRSA-confirmed cSSTIs.	Linezolid	79-88	solute carrier family 9 member A6	Homo sapiens	147-151
20837755-0	2010	Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.	Linezolid	9-18	23S rRNA methylase	Staphylococcus aureus	42-45
20837755-1	2010	Resistance to linezolid (LZD) occurs through mutations in 23S rRNA and ribosomal proteins L3 and L4 or through methylation of 23S rRNA by Cfr.	Linezolid	14-23	23S rRNA methylase	Staphylococcus aureus	138-141
20837755-1	2010	Resistance to linezolid (LZD) occurs through mutations in 23S rRNA and ribosomal proteins L3 and L4 or through methylation of 23S rRNA by Cfr.	Linezolid	25-28	23S rRNA methylase	Staphylococcus aureus	138-141
20837755-2	2010	Here we report novel L3 mutations, DeltaSer145/His146Tyr and DeltaMet169-Gly174, co-occurring with cfr in LZD-resistant Staphylococcus aureus isolates recovered from a hospital outbreak in Madrid, Spain.	Linezolid	106-109	23S rRNA methylase	Staphylococcus aureus	99-102
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	interleukin 1 beta	Homo sapiens	63-71
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	interleukin 6	Homo sapiens	73-77
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	C-X-C motif chemokine ligand 8	Homo sapiens	79-83
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	tumor necrosis factor	Homo sapiens	88-97
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	interleukin 6	Homo sapiens	171-175
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	C-X-C motif chemokine ligand 8	Homo sapiens	177-181
20557833-8	2010	The addition of linezolid significantly reduced mRNA levels of IL-1beta, IL-6, IL-8 and TNF-alpha; (p < 0.05) after 2 and 4 h. LPS stimulation also increased levels of IL-6, IL-8 and TNF-alpha between 100 and 1000-fold.	Linezolid	16-25	tumor necrosis factor	Homo sapiens	186-195
24179347-0	2008	Hepatocyte growth factor level in cerebrospinal fluid as an additional marker in patient with drug-resistant streptococcus pneumoniae meningitis treated with linezolid.	Linezolid	158-167	hepatocyte growth factor	Homo sapiens	0-24
20094752-9	2010	To conclude: (1) it appears possible that LZD inhibits the production of INF-gamma and TNF-alpha to a limited extent; (2) LZD did not exert any inhibitory effect on endotoxin production by bacteria, while suppressing cytokine production.	Linezolid	42-45	tumor necrosis factor	Homo sapiens	87-96
20144045-0	2010	Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.	Linezolid	14-23	23S rRNA methylase	Staphylococcus aureus	43-46
20144045-0	2010	Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.	Linezolid	90-99	23S rRNA methylase	Staphylococcus aureus	43-46
20144045-11	2010	CONCLUSIONS: We report the presence of the cfr gene underlying the resistance mechanism involved in a clinical outbreak of linezolid-resistant S. aureus.	Linezolid	123-132	23S rRNA methylase	Staphylococcus aureus	43-46
20433254-11	2010	The CSF was clear of bacterial growth within a mean of 3.67 +/- 1.36 days (range 2-6 days) after initiation of linezolid treatment.	Linezolid	111-120	colony stimulating factor 2	Homo sapiens	4-7
20001574-0	2010	Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.	Linezolid	23-32	solute carrier family 9 member A6	Homo sapiens	81-85
20001574-10	2010	Microbiological eradication in MRSA ME patients consistently favored the use of linezolid over vancomycin (OR = 2.90; 95% CI: 1.90, 4.41).	Linezolid	80-89	solute carrier family 9 member A6	Homo sapiens	31-35
20001574-15	2010	CONCLUSION: Resolution of infection in CE and MITT patients were inconsistent; however, a sub-analysis revealed that linezolid was more likely to consistently achieve microbiologic eradication in MRSA ME patients.	Linezolid	117-126	solute carrier family 9 member A6	Homo sapiens	196-200
20001574-16	2010	Apparent risks of thrombocytopenia, nausea, diarrhea, and possibly anemia may limit linezolid use in treating MRSA cSSTI.	Linezolid	84-93	solute carrier family 9 member A6	Homo sapiens	110-120
20587984-6	2010	However, after administration of linezolid (LZD) for 14 days, the infection had improved, and the white blood cell count and C-reactive protein values had normalized.	Linezolid	33-42	C-reactive protein	Homo sapiens	125-143
20587984-11	2010	After administration of LZD for 14 days intravenously and 14 days orally, the infection had improved, and the white blood cell count and C-reactive protein values had normalized.	Linezolid	24-27	C-reactive protein	Homo sapiens	137-155
19438638-3	2009	The objective of this study was to compare the efficacy and safety of a combination of rifampicin and linezolid (RLC) with those of a combination of rifampicin and cotrimoxazole (RCC) in the treatment of BJI.	Linezolid	102-111	integrin subunit alpha 9	Homo sapiens	113-116
18980841-2	2008	Clinical complications of newly introduced antibiotic Linezolid, due its MAO inhibitory activity, prompted us to evaluate our compounds for their MAO-inhibitory activity against rat liver MAO-A and MAO-B as pyrazolines were reported to be antidepressants and MAO inhibitors.	Linezolid	54-63	monoamine oxidase A	Rattus norvegicus	73-76
18980841-2	2008	Clinical complications of newly introduced antibiotic Linezolid, due its MAO inhibitory activity, prompted us to evaluate our compounds for their MAO-inhibitory activity against rat liver MAO-A and MAO-B as pyrazolines were reported to be antidepressants and MAO inhibitors.	Linezolid	54-63	monoamine oxidase A	Rattus norvegicus	188-193
18980841-2	2008	Clinical complications of newly introduced antibiotic Linezolid, due its MAO inhibitory activity, prompted us to evaluate our compounds for their MAO-inhibitory activity against rat liver MAO-A and MAO-B as pyrazolines were reported to be antidepressants and MAO inhibitors.	Linezolid	54-63	monoamine oxidase B	Rattus norvegicus	198-203
18727801-5	2008	Extracellular (broth) and intracellular (THP-1 macrophages) activities of rifampicin, linezolid and fusidic acid at C(max), and of vancomycin, daptomycin, quinupristin-dalfopristin and oritavancin over a wide range of extracellular concentrations (with pharmacological modelling to determine E(max)), were measured at 24 h. Increases in vancomycin MICs correlated with increased drug binding, and decreased cell wall turnover and detergent-induced autolysis.	Linezolid	86-95	GLI family zinc finger 2	Homo sapiens	41-46
18391032-1	2008	Linezolid resistance has dominantly been mediated by mutations in 23S rRNA or ribosomal protein L4 genes.	Linezolid	0-9	ribosomal protein L4	Homo sapiens	78-98
16781153-0	2006	Synthesis of novel tricyclic oxazolidinones by a tandem SN2 and SNAr reaction: SAR studies on conformationally constrained analogues of Linezolid.	Linezolid	136-145	solute carrier family 38 member 5	Homo sapiens	56-59
18272512-2	2008	METHODS: An outbreak of colonization with linezolid-resistant S. epidermidis affecting 16 patients in an ITU was investigated using PFGE.	Linezolid	42-51	sulfatase modifying factor 2	Homo sapiens	132-136
18155521-3	2008	Though the SAR resulted in novel compounds possessing in vitro activity equivalent to Linezolid, the compounds possess a range of substituents that are amenable for altering physicochemical properties of the resultant drug.	Linezolid	86-95	sarcosine dehydrogenase	Homo sapiens	11-14
16781153-0	2006	Synthesis of novel tricyclic oxazolidinones by a tandem SN2 and SNAr reaction: SAR studies on conformationally constrained analogues of Linezolid.	Linezolid	136-145	sarcosine dehydrogenase	Homo sapiens	79-82
16431044-2	2006	In this study, the determination of the protein binding of the antibiotics gatifloxacin, moxifloxacin, linezolid and telithromycin to bovine serum albumin (BSA) and human serum albumin (HSA) was performed by means of an automated continuous ultrafiltration method.	Linezolid	103-112	albumin	Homo sapiens	141-160
16431044-2	2006	In this study, the determination of the protein binding of the antibiotics gatifloxacin, moxifloxacin, linezolid and telithromycin to bovine serum albumin (BSA) and human serum albumin (HSA) was performed by means of an automated continuous ultrafiltration method.	Linezolid	103-112	albumin	Homo sapiens	141-154
15521893-1	2004	AIMS: To investigate the effect of monoamine oxidase A inhibition from a single oral dose of linezolid on the pressor response to intravenous (i.v.)	Linezolid	93-102	monoamine oxidase A	Homo sapiens	35-54
15780422-0	2005	Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin.	Linezolid	121-130	mitochondrial antiviral signaling protein	Homo sapiens	87-92
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	31-40	monoamine oxidase A	Homo sapiens	80-99
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	31-40	monoamine oxidase A	Homo sapiens	101-106
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	54-59	monoamine oxidase A	Homo sapiens	80-99
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	54-59	monoamine oxidase A	Homo sapiens	101-106
15194129-8	2004	Linezolid was active against all the isolates tested and tetracycline resistance was the major one in VGS (41.6%) and Gemella spp.	Linezolid	0-9	histocompatibility minor 13	Homo sapiens	126-129
15277016-12	2004	The predicted human values for CL (4.68 l h(-1)), Vss (37.07 litres), and K10 (0.10 h(-1)) were within the range observed for linezolid in the literature (CL = 4-10.5 l h(-1); Vss = 21-53 litres; K10 = 0.09-0.3 h(-1)).	Linezolid	126-135	keratin 10	Homo sapiens	74-77
11336106-2	2001	Because linezolid also competitively inhibits human monoamine oxidase-A (MAO-A; Ki = 55 microM), we monitored its effects on the cardiovascular responses to tyramine and amine cold remedies in comparison with standard MAO inhibitors.	Linezolid	8-17	monoamine oxidase A	Homo sapiens	52-71
14767588-0	2004	Linezolid in VAP by MRSA: a better choice?	Linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	20-24
14622995-4	2003	The synthesis of linezolid analogues possessing the ethylene-oxy spacer group along with SAR studies with different heterocycles and preparation of some thiocarbonyl compounds possessing potent antibacterial property are presented.	Linezolid	17-26	sarcosine dehydrogenase	Homo sapiens	89-92
14561977-1	2003	OBJECTIVE: The purpose of this study was to quantify the cytokines interleukin (IL)-1 receptor antagonist (RA), IL-6, and transforming growth factor beta(1) found in extracts of inflammatory periapical tissues and to study the effect of a new antibiotic (linezolid) on the levels of these cytokines.	Linezolid	255-264	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	149-156
14561977-6	2003	A statistically significant reduction in IL-1RA per milliliter was observed in the linezolid group in comparison with the control group (P <.05).	Linezolid	83-92	interleukin 1 receptor antagonist	Homo sapiens	41-47
12594655-0	2003	Persistent MRSA bacteremia in a patient with low linezolid levels.	Linezolid	49-58	solute carrier family 9 member A6	Homo sapiens	11-15
14742208-3	2004	When added to S. aureus cultures at an OD(540) of 0.05, linezolid reduced in a dose-dependent manner the secretion of specific virulence factors, including staphylococcal enterotoxin A (SEA) and SEB, bifunctional autolysin, autolysin, protein A, and alpha- and beta-hemolysins.	Linezolid	56-65	AT695_RS05875	Staphylococcus aureus	213-222
14742208-3	2004	When added to S. aureus cultures at an OD(540) of 0.05, linezolid reduced in a dose-dependent manner the secretion of specific virulence factors, including staphylococcal enterotoxin A (SEA) and SEB, bifunctional autolysin, autolysin, protein A, and alpha- and beta-hemolysins.	Linezolid	56-65	AT695_RS05875	Staphylococcus aureus	224-233
14531724-18	2003	Linezolid is a mild, reversible, inhibitor of monoamine oxidases A and B.	Linezolid	0-9	monoamine oxidase A	Homo sapiens	46-72
12096009-8	2002	Mean concentrations of linezolid in the haematoma fluid drained from around the operation site were 8.2 mg/L at 6-8 h and 5.6 mg/L at 10-12 h after the infusion, and 7.0 mg/L at 2-4 h following a second 600 mg infusion given 12 h post-operatively.	Linezolid	23-32	linker for activation of T cells family member 2	Homo sapiens	173-181
11336106-2	2001	Because linezolid also competitively inhibits human monoamine oxidase-A (MAO-A; Ki = 55 microM), we monitored its effects on the cardiovascular responses to tyramine and amine cold remedies in comparison with standard MAO inhibitors.	Linezolid	8-17	monoamine oxidase A	Homo sapiens	73-78
10354862-1	1999	We report the activity of the new oxazolidinone antimicrobial agent linezolid against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 20 clinical isolates of high-level penicillin-resistant S. pneumoniae.	Linezolid	68-77	D-alanine--D-lactate ligase	Staphylococcus aureus	183-187
33940510-0	2021	In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5.	Linezolid	3-12	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	66-72
33805734-3	2021	Two isolates carrying linezolid resistance genes were recovered from laryngological patients and characterized by determining their antimicrobial resistance patterns and using molecular methods such as spa typing, MLST, SCCmec typing, detection of virulence genes and ica operon expression, and analysis of antimicrobial resistance determinants.	Linezolid	22-31	surfactant protein A1	Homo sapiens	202-205
33940510-8	2021	Our data suggest that CYP3A5 polymorphisms might significantly affect linezolid disposition, putting patients at higher risk to be underexposed, while P-glycoprotein polymorphism seem not to play any role.	Linezolid	70-79	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	22-28
34675806-4	2021	The population pharmacokinetic model of linezolid was established based on 270 plasma concentrations in 152 patients, which showed creatinine clearance and white cell count are covariates affecting the clearance of linezolid, and serum albumin is the covariate affecting the volume of distribution.	Linezolid	40-49	albumin	Homo sapiens	230-243
34871098-7	2022	The average daily decline in log-cfu was 0.192+-0.028 for the HRZE group and 0.154+-0.023 for the linezolid 600 mg BID group.	Linezolid	98-107	BH3 interacting domain death agonist	Homo sapiens	115-118
33820765-5	2021	The dose of linezolid needed to achieve a PTA >= 90% for all susceptible isolates classified according to EUCAST was estimated to be as high as 2400mg/12h, which is 4 times higher than the maximum licensed linezolid dose.The final pk model was then used to construct software for dosage individualisation and the performance of the software was assessed using 10 new patients not used to construct the original population PK model.A three-compartment model with an absorptive compartment with zero-order i.v.	Linezolid	12-21	calpastatin	Homo sapiens	106-112
34356479-9	2021	In conclusion, azithromycin combinations with either linezolid, or ceftriaxone showed synergism in most of the MAC-resistant MRSA clinical isolates.	Linezolid	53-62	solute carrier family 9 member A6	Homo sapiens	125-129
34158725-1	2020	Linezolid is an oxazolidinone antibiotic, which is a weak, reversible, nonselective monoamine oxidase A and B inhibitor; is known to increase serotonin levels, and has been implicated in the development of serotonin syndrome (SS).	Linezolid	0-9	monoamine oxidase A	Homo sapiens	84-109
34356479-7	2021	Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively.	Linezolid	38-47	solute carrier family 9 member A6	Homo sapiens	151-155
34281189-2	2021	The mechanism of interaction of chiral oxazolidinone ligands belonging to a new class of antibacterial agents, such as linezolid, tedizolid, radezolid, and sutezolid, with HDAS-beta-CD based on capillary electrokinetic chromatography (cEKC), nuclear magnetic resonance (NMR) spectroscopy, and MM methods was described.	Linezolid	119-128	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	177-184
35490314-9	2022	Among five tested antibiotics, moderate inhibition on OAT3-mediated meropenem uptake was observed for linezolid (IC50 value was 69.2 muM), weak inhibition was observed for piperacillin, benzylpenicillin and tazobactam (IC50 values were 282.2, 308.0 and 668.1 muM, respectively), and no inhibition was observed for sulbactam.	Linezolid	102-111	solute carrier family 22 member 8	Rattus norvegicus	54-58
35240740-20	2022	The predominant serotypes are 19F and 19A and all isolated strains were susceptible to vancomycin and linezolid.	Linezolid	102-111	SLAM family member 7	Homo sapiens	38-41
35042700-0	2022	Linezolid Metabolism is Catalyzed by CYP2J2, CYP4F2 and CYP1B1.	Linezolid	0-9	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
35042700-0	2022	Linezolid Metabolism is Catalyzed by CYP2J2, CYP4F2 and CYP1B1.	Linezolid	0-9	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	45-51
35042700-0	2022	Linezolid Metabolism is Catalyzed by CYP2J2, CYP4F2 and CYP1B1.	Linezolid	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	56-62
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	Linezolid	103-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	Linezolid	103-112	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	145-151
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	Linezolid	231-240	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	Linezolid	231-240	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	145-151
35042700-5	2022	These experiments suggest that CYP2J2 and CYP4F2 contribute about 50% each to linezolid hepatic metabolism.	Linezolid	78-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
35042700-5	2022	These experiments suggest that CYP2J2 and CYP4F2 contribute about 50% each to linezolid hepatic metabolism.	Linezolid	78-87	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	42-48
33785363-8	2021	90-day IRR occurred in 17% and 26% of the linezolid and SPT groups, respectively (P=0.185).	Linezolid	42-51	insulin receptor related receptor	Homo sapiens	7-10
35209803-5	2022	The serum linezolid levels in 22 and 15 patients were within and above the therapeutic range (2-7 microg/mL), respectively.	Linezolid	10-19	thrombopoietin	Mus musculus	105-107
35044221-14	2022	Subinhibitory concentrations (sub-MIC) of antibiotics modulate in vitro toxins expression in S. aureus: clindamycin (CLI) and linezolid (LIN) display an anti-toxin effect on Panton-Valentine leucocidin and alpha-hemolysin production, while oxacillin (OXA) has an inducing effect.	Linezolid	126-135	AT695_RS11870	Staphylococcus aureus	206-221
33913699-1	2021	Linezolid, the principal oxazolidinone antibiotic for therapy of Gram-positive infections, is limited by its myelosuppression and monoamine oxidase (MAO) inhibition, with the latter manifested as serotonergic neurotoxicity.	Linezolid	0-9	monoamine oxidase A	Rattus norvegicus	149-152
33913699-4	2021	Contezolid exhibited 2- and 148-fold reduction over linezolid reversible inhibition of MAO-A and MAO-B human enzyme isoforms.	Linezolid	52-61	monoamine oxidase A	Homo sapiens	87-92
33913699-4	2021	Contezolid exhibited 2- and 148-fold reduction over linezolid reversible inhibition of MAO-A and MAO-B human enzyme isoforms.	Linezolid	52-61	monoamine oxidase B	Homo sapiens	97-102
33551346-6	2021	The aspirated fluid was sent for culture and sensitivity that revealed MRSA sensitive to vancomycin and linezolid.	Linezolid	104-113	solute carrier family 9 member A6	Homo sapiens	71-75
33609520-3	2021	To predict linezolid-induced thrombocytopenia, classification and regression tree (CART) analysis based on machine learning has been applied to identify predictive factors and cutoff values.	Linezolid	11-20	CART prepropeptide	Homo sapiens	83-87
33609520-6	2021	CART analysis selected the final tree containing two cutoff values: a platelet count reduction to less than 2.3% from baseline at 96 hours after the initial dose and a linezolid concentration greater than or equal to 13.5 mg/L at 96 hours after the initial dose.	Linezolid	168-177	CART prepropeptide	Homo sapiens	0-4
33147717-0	2020	Emergence of cfr-Mediated Linezolid Resistance in Staphylococcus aureus Isolated from Pig Carcasses.	Linezolid	26-35	23S rRNA methylase	Staphylococcus aureus	13-16
33596041-21	2021	(R)-ND-336 in combination with the antibiotic linezolid improved wound healing in infected diabetic mice by inhibiting MMP-9, which mitigated macrophage infiltration and increased angiogenesis, thereby restoring the normal wound healing process.	Linezolid	46-55	matrix metallopeptidase 9	Mus musculus	119-124
33558298-10	2021	Body weight and aspartate aminotransferase (AST) were the most significant covariates explaining variabilities in linezolid PK for the pediatric population.	Linezolid	114-123	solute carrier family 17 member 5	Homo sapiens	44-47
33173316-0	2020	First Report Cfr and Optr A Co-harboring Linezolid-Resistant Enterococcus faecalis in China.	Linezolid	41-50	chloramphenicol-florfenicol resistance protein, CFR	Enterococcus faecalis	13-16
33173316-1	2020	A linezolid-resistant E.faecalis strain harboring optrA and cfr resistance genes were isolated from a patient in china, which had no mutations in rplC, rplD, rplV, and 23S rRNA gene.	Linezolid	2-11	chloramphenicol-florfenicol resistance protein, CFR	Enterococcus faecalis	60-63
33173316-2	2020	Transformation indicated that optrA and cfr were located on two different plasmids and both could be transferred to recipient strain, resulting in the increase of MICs of linezolid and chloramphenicol.	Linezolid	171-180	chloramphenicol-florfenicol resistance protein, CFR	Enterococcus faecalis	40-43
33251375-10	2020	Linezolid, one of the oxazo-lidinones, was initially given in oral form 600 mg BID for three weeks, but did not prove efficacious.	Linezolid	0-9	BH3 interacting domain death agonist	Homo sapiens	79-82
33009444-0	2020	Contrasting effects of linezolid on healthy and dysfunctional human neutrophils: reducing C5a-induced injury.	Linezolid	23-32	complement C5a receptor 1	Homo sapiens	90-93
33060737-0	2020	In vivo bactericidal effect of colistin-linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia.	Linezolid	40-49	malic enzyme complex, mitochondrial	Mus musculus	83-86
32477361-7	2020	We hypothesized LZD efficacy could be enhanced by modulation of IL-1 pathway to reduce bone marrow toxicity and TB associated-inflammation.	Linezolid	16-19	interleukin 1 alpha	Homo sapiens	64-68
32360800-5	2020	Additionally, LZD significantly reduced colonic inflammation in UC mice by inhibiting the production of bone marrow peroxidase (MPO), superoxide dismutase (SOD), nitric oxide (NO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta and IL-6).	Linezolid	14-17	myeloperoxidase	Mus musculus	128-131
32360800-5	2020	Additionally, LZD significantly reduced colonic inflammation in UC mice by inhibiting the production of bone marrow peroxidase (MPO), superoxide dismutase (SOD), nitric oxide (NO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta and IL-6).	Linezolid	14-17	tumor necrosis factor	Mus musculus	195-204
32360800-5	2020	Additionally, LZD significantly reduced colonic inflammation in UC mice by inhibiting the production of bone marrow peroxidase (MPO), superoxide dismutase (SOD), nitric oxide (NO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta and IL-6).	Linezolid	14-17	interferon gamma	Mus musculus	206-215
32360800-5	2020	Additionally, LZD significantly reduced colonic inflammation in UC mice by inhibiting the production of bone marrow peroxidase (MPO), superoxide dismutase (SOD), nitric oxide (NO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta and IL-6).	Linezolid	14-17	interleukin 1 alpha	Mus musculus	217-225
32360800-5	2020	Additionally, LZD significantly reduced colonic inflammation in UC mice by inhibiting the production of bone marrow peroxidase (MPO), superoxide dismutase (SOD), nitric oxide (NO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta and IL-6).	Linezolid	14-17	interleukin 6	Mus musculus	230-234
32360800-6	2020	And the expressions of TLR4 and NF-kappaB mRNA in UC mice were remarkably down-regulated after the treatment of LZD.	Linezolid	112-115	toll-like receptor 4	Mus musculus	23-27
33615165-7	2021	We evaluated the efficacy of the selective small-molecule MMP-9 inhibitor, (R)-ND-336, in the infected diabetic mouse model of wound healing and showed that (R)-ND-336 alone or in combination with the antibiotic linezolid improves wound healing by inhibiting the detrimental MMP-9, mitigating macrophage infiltration to diminish inflammation, and increasing angiogenesis to restore the normal wound healing process.	Linezolid	212-221	matrix metallopeptidase 9	Mus musculus	58-63
32350737-9	2020	Linezolid resistance was associated with acquisition of A157R mutation in the ribosomal protein L3 and the presence of cfr gene.	Linezolid	0-9	ribosomal protein L3	Homo sapiens	78-98
33015768-9	2020	The emergence of the novel plasmid-borne ABC transporter gene optrA expanded the understanding of the mechanism of linezolid resistance.	Linezolid	115-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	41-56
33132425-9	2020	Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy.	Linezolid	139-142	C-reactive protein	Homo sapiens	67-70
33132425-9	2020	Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy.	Linezolid	198-201	C-reactive protein	Homo sapiens	67-70
32477361-12	2020	However, total lung inflammation was significantly reduced in macaques treated with IL-1Rn and LZD compared to LZD alone.	Linezolid	111-114	interleukin 1 receptor antagonist	Mus musculus	84-90
30623345-13	2020	CONCLUSION: LZD can significantly suppress VR induced by AMI, and its underlying mechanism may be associated with its inhibitory effect on the TGF-beta1/Smad signaling pathway.	Linezolid	12-15	transforming growth factor, beta 1	Mus musculus	143-152
31208925-7	2019	The CRP concentrations decreased more than 50% in all pediatric patients after the treatment with linezolid, however body temperatures at the end of treatment were higher than 37.5  C in 6 patients (42.9%).	Linezolid	98-107	C-reactive protein	Homo sapiens	4-7
32084018-9	2019	Using the univariate analysis advanced sex, serum urea concentration, baseline platelet level and low eGFR value were found to be risk factors for linezolid associated thrombocytopenia (p < 0.05).	Linezolid	147-156	epidermal growth factor receptor	Homo sapiens	102-106
31931914-1	2019	SETTING: Studies have shown that linezolid (LZD) can be used to treat extensively drug-resistant tuberculosis (XDR-TB).OBJECTIVE: To conduct a systematic review and meta-analysis to assess existing evidence concerning efficacy and safety of LZD for XDR-TB treatment.DESIGN: The MEDLINE@OVID, PubMed, EMBASE, the Cochrane Library, Clinical Trials, Sinomed, CMCI, CNKI, VIP and Wanfang databases were systematically searched for randomised controlled trials, cohort studies, case series or case reports on XDR-TB patients treated with LZD from January 2000 to December 2016.	Linezolid	33-42	vasoactive intestinal peptide	Homo sapiens	368-371
31931914-1	2019	SETTING: Studies have shown that linezolid (LZD) can be used to treat extensively drug-resistant tuberculosis (XDR-TB).OBJECTIVE: To conduct a systematic review and meta-analysis to assess existing evidence concerning efficacy and safety of LZD for XDR-TB treatment.DESIGN: The MEDLINE@OVID, PubMed, EMBASE, the Cochrane Library, Clinical Trials, Sinomed, CMCI, CNKI, VIP and Wanfang databases were systematically searched for randomised controlled trials, cohort studies, case series or case reports on XDR-TB patients treated with LZD from January 2000 to December 2016.	Linezolid	44-47	vasoactive intestinal peptide	Homo sapiens	368-371
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	Linezolid	44-53	solute carrier family 9 member A6	Homo sapiens	0-4
31383747-4	2019	Furthermore, we found that the protein synthesis-suppressing antibiotic linezolid has an advantageous therapeutic effect on alpha-toxin-induced lung damage, as measured by protein leak and lactate dehydrogenase (LDH) activity.	Linezolid	72-81	AT695_RS04475	Staphylococcus aureus	189-210
31383747-4	2019	Furthermore, we found that the protein synthesis-suppressing antibiotic linezolid has an advantageous therapeutic effect on alpha-toxin-induced lung damage, as measured by protein leak and lactate dehydrogenase (LDH) activity.	Linezolid	72-81	AT695_RS04475	Staphylococcus aureus	212-215
30212947-0	2018	Effect of linezolid on serum PCT, ESR, and CRP in patients with pulmonary tuberculosis and pneumonia.	Linezolid	10-19	C-reactive protein	Homo sapiens	43-46
30883521-0	2019	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.	Linezolid	131-140	ATP binding cassette subfamily B member 1	Homo sapiens	155-160
30883522-0	2019	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.	Linezolid	131-140	ATP binding cassette subfamily B member 1	Homo sapiens	155-160
30535122-11	2019	Standard linezolid dosing in obese pneumonia patients with MRSA (MICs of 1-4 mg/L) leads to unacceptably low (near zero to 60%) PTA for patients <65 years old.	Linezolid	9-18	solute carrier family 9 member A6	Homo sapiens	59-63
30535122-13	2019	Body weight and especially age are important characteristics to be considered when administering linezolid to treat MRSA infections.	Linezolid	97-106	solute carrier family 9 member A6	Homo sapiens	116-120
30372832-10	2018	The linezolid induced liver damage was confirmed by elevation of marker enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) levels, serum bilirubin, lactate, and histopathological studies of the liver.	Linezolid	4-13	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	112-138
30372832-10	2018	The linezolid induced liver damage was confirmed by elevation of marker enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) levels, serum bilirubin, lactate, and histopathological studies of the liver.	Linezolid	4-13	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	140-143
30940534-1	2019	Linezolid-resistant enterococcus spp.	Linezolid	0-9	histocompatibility minor 13	Homo sapiens	33-36
29979333-0	2018	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance.	Linezolid	62-71	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
29979333-2	2018	Very recently, it has been suggested that linezolid could be an ABCB1 substrate.	Linezolid	42-51	ATP binding cassette subfamily B member 1	Homo sapiens	64-69
29979333-3	2018	Therefore, the present clinical study was aimed at investigating whether ABCB1 polymorphisms could predict linezolid pharmacokinetics in 27 critically ill patients.	Linezolid	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	73-78
29979333-5	2018	RESULTS: A significant effect of abcb1 c.3435C>T polymorphism on linezolid clearance was found, whose values accounted for 13.19 L/h in wild-type homozygotes and 7.82 L/h in the remaining individuals.	Linezolid	68-77	ATP binding cassette subfamily B member 1	Homo sapiens	33-38
29979333-10	2018	CONCLUSIONS: The obtained results suggest the possible influence of ABCB1 in linezolid pharmacokinetics, bringing new interest for pharmacogenetic analyses in antimicrobial chemotherapy.	Linezolid	77-86	ATP binding cassette subfamily B member 1	Homo sapiens	68-73
30212947-12	2018	CONCLUSION: In the treatment of tuberculosis and pneumonia, linezolid can improve serum PCT, ESR, and CRP levels, and eradicate bacteria.	Linezolid	60-69	C-reactive protein	Homo sapiens	102-105
29853968-10	2018	The LZD-medicated serum also increased the autophagosomes and the autophagic protein expressions of LC3-II and Beclin-1.	Linezolid	4-7	beclin 1	Homo sapiens	111-119
29668933-8	2018	The swine linezolid resistant ST22 did not carry any known acquired linezolid resistance genes but had a mutation in ribosomal protein L22 [A29V] and an insertion in L4 [68KG69], both previously associated with linezolid resistance.	Linezolid	10-19	60S ribosomal protein L22	Sus scrofa	117-138
29263063-0	2018	Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes.	Linezolid	128-137	GLI family zinc finger 2	Homo sapiens	232-237
29149185-8	2017	Linezolid alone dampened TNF-alpha lung production in both SB and MV rabbits (e.g., 2226 [789] vs. 11478 [10251] pg/g; p = 0.022).	Linezolid	0-9	tumor necrosis factor	Oryctolagus cuniculus	25-34
29324625-1	2018	BACKGROUND: An enzymatic immunoassay is under development by ARK Diagnostics, Inc for the quantification of plasma concentrations of linezolid (LZD).	Linezolid	133-142	AXL receptor tyrosine kinase	Homo sapiens	61-64
29324625-1	2018	BACKGROUND: An enzymatic immunoassay is under development by ARK Diagnostics, Inc for the quantification of plasma concentrations of linezolid (LZD).	Linezolid	144-147	AXL receptor tyrosine kinase	Homo sapiens	61-64
27774857-1	2017	In this study, in vitro synergism in combinations of agents as ceftriaxone/dalbavancin, ceftriaxone/linezolid and ceftriaxone/daptomycin against MRSA strains were investigated.	Linezolid	100-109	solute carrier family 9 member A6	Homo sapiens	145-149
29311467-5	2018	Cytotoxicity of linezolid was relieved by the knockdown of superoxide dismutase-1 in U937 cells.	Linezolid	16-25	superoxide dismutase 1	Homo sapiens	59-81
28821804-8	2017	Linezolid was bacteriostatic in TB-infected Nos2 -/- mice but significantly improved lung pathology.	Linezolid	0-9	nitric oxide synthase 2, inducible	Mus musculus	44-48
28600981-7	2017	Linezolid, at therapeutic concentrations, modifies the levels of apolipoprotein E and several adipokines and proteins related with the extracellular matrix.	Linezolid	0-9	apolipoprotein E	Homo sapiens	65-81
28186644-6	2017	The decrease platelets by linezolid exposure was assumed to occur by one of two mechanisms: inhibition of the formation of platelets (PDI) or stimulation of the elimination (PDS) of platelets.	Linezolid	26-35	peptidyl arginine deiminase 1	Homo sapiens	134-137
28186644-12	2017	This combined pharmacokinetic, pharmacodynamic and turnover model identified that the most common mechanism of thrombocytopenia associated with linezolid is PDI.	Linezolid	144-153	peptidyl arginine deiminase 1	Homo sapiens	157-160
27034576-1	2016	Linezolid is an oxazolidinone antibiotic with weak monoamine oxidase (MAO) type A and MAO type B inhibitory effects.	Linezolid	0-9	monoamine oxidase A	Homo sapiens	51-81
28343752-5	2017	RESULTS: The tedizolid and linezolid MICs for MRSA was 0.25 and 2 mug/ml.	Linezolid	27-36	solute carrier family 9 member A6	Homo sapiens	46-50
28343752-9	2017	CONCLUSION: In the neutropenic murine thigh infection model, human simulated exposures of tedizolid and linezolid resulted in similar efficacies against MRSA, even though single and mixed infection models were used.	Linezolid	104-113	solute carrier family 9 member A6	Homo sapiens	153-157
28314920-7	2017	The oxazolidinone tedizolid is effective against linezolid-resistant MRSA.	Linezolid	49-58	solute carrier family 9 member A6	Homo sapiens	69-73
26872906-2	2016	We observed the retina using Fourier-domain optical coherence tomography (FD-OCT) in a patient with linezolid-induced optic neuropathy.	Linezolid	100-109	plexin A2	Homo sapiens	77-80
27259840-9	2016	Although there were no significant differences in the bacterial count in the lungs amongst the drugs at 26h post-inoculation, TZD and LZD significantly improved the plasma concentrations of TNF-alpha, IL-6 and MIP-2, in comparison with the control.	Linezolid	134-137	tumor necrosis factor	Mus musculus	190-199
27259840-9	2016	Although there were no significant differences in the bacterial count in the lungs amongst the drugs at 26h post-inoculation, TZD and LZD significantly improved the plasma concentrations of TNF-alpha, IL-6 and MIP-2, in comparison with the control.	Linezolid	134-137	interleukin 6	Mus musculus	201-205
27259840-9	2016	Although there were no significant differences in the bacterial count in the lungs amongst the drugs at 26h post-inoculation, TZD and LZD significantly improved the plasma concentrations of TNF-alpha, IL-6 and MIP-2, in comparison with the control.	Linezolid	134-137	chemokine (C-X-C motif) ligand 2	Mus musculus	210-215
26431268-0	2016	Role of linezolid therapeutic drug monitoring in the treatment of MRSA tracheo-pulmonary infection in a 10-month-old infant.	Linezolid	8-17	solute carrier family 9 member A6	Homo sapiens	66-70
27742640-13	2016	CONCLUSIONS:  We have developed an oral faropenem-linezolid-moxifloxacin (FLAME) regimen that is free of first-line drugs.	Linezolid	50-59	CASP8 and FADD like apoptosis regulator	Homo sapiens	74-79
27324768-8	2016	Independent covariates related to significant decreases of linezolid concentrations included higher weight, creatinine clearance rates, and fibrinogen and antithrombin concentrations, lower concentrations of lactate, and the presence of acute respiratory distress syndrome (ARDS).	Linezolid	59-68	fibrinogen beta chain	Homo sapiens	140-150
27324768-8	2016	Independent covariates related to significant decreases of linezolid concentrations included higher weight, creatinine clearance rates, and fibrinogen and antithrombin concentrations, lower concentrations of lactate, and the presence of acute respiratory distress syndrome (ARDS).	Linezolid	59-68	serpin family C member 1	Homo sapiens	155-167
27324768-9	2016	Linezolid clearance was increased in ARDS patients (by 82%) and in patients with elevated fibrinogen or decreased lactate concentrations.	Linezolid	0-9	fibrinogen beta chain	Homo sapiens	90-100
27520338-8	2016	In particular, 100 % categorical agreement was found with levofloxacin for Enterobacteriaceae by both PR1 and PR2, and 99.0 and 100 % categorical agreement was observed with linezolid for Gram-positive cocci by PR1 and PR2, respectively.	Linezolid	174-183	transmembrane protein 37	Homo sapiens	211-214
27073268-0	2016	Linezolid-resistant cfr-positive MRSA, Italy.	Linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	33-37
26953211-2	2016	An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.	Linezolid	27-36	50S ribosomal protein L3	Mycobacterium tuberculosis H37Rv	131-135
26953211-2	2016	An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.	Linezolid	27-36	50S ribosomal protein L3	Mycobacterium tuberculosis H37Rv	183-187
26953211-2	2016	An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.	Linezolid	38-41	50S ribosomal protein L3	Mycobacterium tuberculosis H37Rv	131-135
26953211-2	2016	An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.	Linezolid	243-246	50S ribosomal protein L3	Mycobacterium tuberculosis H37Rv	131-135
26976869-2	2016	Rifabutin, ethambutol, amoxicillin, linezolid, p-amino salicylic acid, and rifapentine exhibited mild to moderate inhibitory effects on OATP-mediated uptake of estrone-3 sulfate, estradiol 17beta-d-glucuronide, and rosuvastatin.	Linezolid	36-45	solute carrier organic anion transporter family member 1A2 L homeolog	Xenopus laevis	136-140
26976869-4	2016	Streptomycin and linezolid showed greater inhibition of organic anionic transporter polypeptide 2B1 (OATP2B1)-mediated uptake, with IC50 values of 33.2 and 35.6 muM, respectively, along with mild inhibition of other drugs.	Linezolid	17-26	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	56-99
26976869-4	2016	Streptomycin and linezolid showed greater inhibition of organic anionic transporter polypeptide 2B1 (OATP2B1)-mediated uptake, with IC50 values of 33.2 and 35.6 muM, respectively, along with mild inhibition of other drugs.	Linezolid	17-26	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	101-108
27803456-0	2016	Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2.	Linezolid	0-9	myosin light chain 2	Homo sapiens	106-126
27803456-7	2016	Lastly, LZD treatment yielded elevated levels of phosphorylation of myosin light chain 2 (MLC2), which regulates platelet release, in MEG-01 cells.	Linezolid	8-11	myosin light chain 2	Homo sapiens	68-88
27803456-7	2016	Lastly, LZD treatment yielded elevated levels of phosphorylation of myosin light chain 2 (MLC2), which regulates platelet release, in MEG-01 cells.	Linezolid	8-11	myosin light chain 2	Homo sapiens	90-94
27803456-8	2016	Based on these results, we speculate that LZD induces thrombocytopenia by promoting MLC2 phosphorylation and thereby suppressing the release of platelets from mature megakaryocytes.	Linezolid	42-45	myosin light chain 2	Homo sapiens	84-88
27904038-8	2016	Univariate and multiple logistic regression analyses identified the plasma C-reactive protein (CRP) level before the initial administration of linezolid and the concomitant use of a potassium-sparing diuretic as the independent variables associated with the development of hyponatremia.	Linezolid	143-152	C-reactive protein	Homo sapiens	75-93
27904038-8	2016	Univariate and multiple logistic regression analyses identified the plasma C-reactive protein (CRP) level before the initial administration of linezolid and the concomitant use of a potassium-sparing diuretic as the independent variables associated with the development of hyponatremia.	Linezolid	143-152	C-reactive protein	Homo sapiens	95-98
26541549-10	2015	When enterococci were also considered, all betalactam based regimens required combination with vancomycin or linezolid for a SAR > 95 %, whereas TGC based regimens were not compromised.	Linezolid	109-118	sarcosine dehydrogenase	Homo sapiens	125-128
25732525-9	2015	WHAT IS NEW AND CONCLUSIONS: This finding suggests that duration of LZD treatment and WBC count (>12000 cells/muL) are risk factors associated with thrombocytopenia resulting from LZD administration.	Linezolid	183-186	tripartite motif containing 37	Homo sapiens	113-116
26382940-0	2015	Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia.	Linezolid	44-53	structural maintenance of chromosomes 3	Homo sapiens	107-138
26382940-10	2015	CONCLUSION: Linezolid was associated with decreased patient mortality compared to vancomycin in a national cohort of non-critically ill, hospitalized veterans with HCAP.	Linezolid	12-21	structural maintenance of chromosomes 3	Homo sapiens	164-168
26198370-2	2015	We conducted a real-world analysis of antibiotic treatment, hospital resource use and clinical outcomes in patients with PVD and/or diabetes receiving linezolid or vancomycin for the treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (MRSA cSSTIs) across Europe.	Linezolid	151-160	solute carrier family 9 member A6	Homo sapiens	285-289
26198370-9	2015	The reduction in resource use may result in lower hospital costs for patients with PVD and/or diabetes and MRSA cSSTIs if treated with linezolid compared with vancomycin.	Linezolid	135-144	solute carrier family 9 member A6	Homo sapiens	107-111
25710940-1	2015	MRX-I is an analog of linezolid containing a 2,3-dihydropyridin-4-one (DHPO) ring rather than a morpholine ring.	Linezolid	22-31	discs large MAGUK scaffold protein 3	Homo sapiens	0-3
25209610-0	2015	Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.	Linezolid	97-106	solute carrier family 9 member A6	Homo sapiens	128-132
25635685-6	2015	As compared to animals receiving Vanco, LZD group had significantly lower numbers of neutrophils in the BAL (9x10(3) vs. 2.3x10(4), p < 0.01), which was associated with reduced levels of chemotactic chemokines and inflammatory cytokines KC, MIP-2, IFN-gamma, TNF-alpha and IL-1beta in the BAL.	Linezolid	40-43	chemokine (C-X-C motif) ligand 2	Mus musculus	244-249
25635685-6	2015	As compared to animals receiving Vanco, LZD group had significantly lower numbers of neutrophils in the BAL (9x10(3) vs. 2.3x10(4), p < 0.01), which was associated with reduced levels of chemotactic chemokines and inflammatory cytokines KC, MIP-2, IFN-gamma, TNF-alpha and IL-1beta in the BAL.	Linezolid	40-43	interferon gamma	Mus musculus	251-260
25635685-6	2015	As compared to animals receiving Vanco, LZD group had significantly lower numbers of neutrophils in the BAL (9x10(3) vs. 2.3x10(4), p < 0.01), which was associated with reduced levels of chemotactic chemokines and inflammatory cytokines KC, MIP-2, IFN-gamma, TNF-alpha and IL-1beta in the BAL.	Linezolid	40-43	tumor necrosis factor	Mus musculus	262-271
25635685-6	2015	As compared to animals receiving Vanco, LZD group had significantly lower numbers of neutrophils in the BAL (9x10(3) vs. 2.3x10(4), p < 0.01), which was associated with reduced levels of chemotactic chemokines and inflammatory cytokines KC, MIP-2, IFN-gamma, TNF-alpha and IL-1beta in the BAL.	Linezolid	40-43	interleukin 1 beta	Mus musculus	276-284
24532601-3	2014	In this study, we infected the human macrophage-like cell line THP-1 with drug-sensitive and drug-resistant M. tuberculosis strains and found that tolerance developed to most antituberculosis drugs, including the newer agents moxifloxacin, PA-824, linezolid, and bedaquiline.	Linezolid	248-257	GLI family zinc finger 2	Homo sapiens	63-68
24620024-7	2014	Analysis of myeloperoxidase activity and Ly6G immunostaining showed a dramatic decrease of neutrophil infiltration in infected lung tissues for linezolid-treated animals.	Linezolid	144-153	myeloperoxidase	Mus musculus	12-27
24620024-7	2014	Analysis of myeloperoxidase activity and Ly6G immunostaining showed a dramatic decrease of neutrophil infiltration in infected lung tissues for linezolid-treated animals.	Linezolid	144-153	lymphocyte antigen 6 complex, locus G	Mus musculus	41-45
24820080-0	2014	Immunomodulatory effect of linezolid on methicillin-resistant Staphylococcus aureus supernatant-induced MUC5AC overexpression in human airway epithelial cells.	Linezolid	27-36	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	104-110
24913359-7	2014	MAIN OUTCOME MEASURE: Linezolid-induced thrombocytopenia was defined as a decrease in the patient"s platelet count to <10 x 104/muL or a reduction of >=30 % from their baseline value.	Linezolid	22-31	tripartite motif containing 37	Homo sapiens	131-134
24820080-3	2014	In this study, we examined the effect of linezolid on MRSA-induced MUC5AC overexpression in airway epithelial cells.	Linezolid	41-50	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	67-73
24820080-7	2014	In an inhibition study, linezolid significantly reduced MRSA-induced MUC5AC protein and mRNA overexpression at concentrations of 5 and 20 mug/ml, which were the same as the trough and peak concentrations in human epithelial lining fluid.	Linezolid	24-33	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	69-75
24820080-9	2014	In addition, the ERK1/2 phosphorylation was inhibited by linezolid.	Linezolid	57-66	mitogen-activated protein kinase 3	Homo sapiens	17-23
24080654-2	2013	Interestingly, subinhibitory concentrations of chloramphenicol in combination with heat stress, as well as linezolid and spectinomycin at physiological temperatures, selected for such rsbU::IS256 insertion mutants.	Linezolid	107-116	IS256, transposase	Staphylococcus aureus	190-195
24690906-12	2014	The results showed that linezolid induces a decrease of WBC, RBC and platelet numbers in rat blood and enzymatic activities of superoxide dismutase and catalase in rat serum in a dose-dependent manner.	Linezolid	24-33	catalase	Rattus norvegicus	152-160
23960042-0	2014	Cfr-mediated linezolid resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus haemolyticus associated with clinical infections in humans: two case reports.	Linezolid	13-22	23S rRNA methylase	Staphylococcus aureus	0-3
23415582-2	2013	We present the case of a 10-year-old girl with severe sepsis caused by a linezolid-resistant E. faecium (Van-B VRE) after multiple trauma and right-sided hemipelvectomy.	Linezolid	73-82	D-alanine--D-lactate ligase	Enterococcus faecium	105-110
24068869-2	2013	Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin.	Linezolid	178-187	solute carrier family 9 member A6	Homo sapiens	157-167
24068869-13	2013	CONCLUSION: Outpatient costs of managing MRSA cSSTI may be reduced by 30%-50% with oral linezolid compared with vancomycin or daptomycin.	Linezolid	88-97	solute carrier family 9 member A6	Homo sapiens	41-51
23954133-3	2013	Here we have identified the oxazolidinone antibiotic linezolid as a Nlrp3 agonist that activates the Nlrp3 inflammasome independently of ROS.	Linezolid	53-62	NLR family pyrin domain containing 3	Homo sapiens	68-73
23954133-3	2013	Here we have identified the oxazolidinone antibiotic linezolid as a Nlrp3 agonist that activates the Nlrp3 inflammasome independently of ROS.	Linezolid	53-62	NLR family pyrin domain containing 3	Homo sapiens	101-106
23833238-0	2013	Linezolid decreases susceptibility to secondary bacterial pneumonia postinfluenza infection in mice through its effects on IFN-gamma.	Linezolid	0-9	interferon gamma	Mus musculus	123-132
23833238-4	2013	Recent data suggest that the oxazolidinone antibiotic linezolid decreases IFN-gamma and TNF-alpha production in vitro from stimulated PBMCs.	Linezolid	54-63	interferon gamma	Mus musculus	74-83
23833238-4	2013	Recent data suggest that the oxazolidinone antibiotic linezolid decreases IFN-gamma and TNF-alpha production in vitro from stimulated PBMCs.	Linezolid	54-63	tumor necrosis factor	Mus musculus	88-97
23833238-5	2013	We therefore sought to determine whether linezolid would reverse immune hyporesponsiveness after influenza infection in mice through its effects on IFN-gamma.	Linezolid	41-50	interferon gamma	Mus musculus	148-157
23833238-6	2013	In vivo dose-response studies demonstrated that oral linezolid administration sufficiently decreased bronchoalveolar lavage fluid levels of IFN-gamma at day 7 postinfluenza infection in a dose-dependent manner.	Linezolid	53-62	interferon gamma	Mus musculus	140-149
23833238-8	2013	When mice were challenged intranasally with Streptococcus pneumoniae 7 d postinfection with influenza, linezolid pretreatment led to decreased IFN-gamma and TNF-alpha production, decreased weight loss, and lower bacterial burdens at 24 h postbacterial infection in comparison with vehicle-treated controls.	Linezolid	103-112	interferon gamma	Rattus norvegicus	143-152
23833238-8	2013	When mice were challenged intranasally with Streptococcus pneumoniae 7 d postinfection with influenza, linezolid pretreatment led to decreased IFN-gamma and TNF-alpha production, decreased weight loss, and lower bacterial burdens at 24 h postbacterial infection in comparison with vehicle-treated controls.	Linezolid	103-112	tumor necrosis factor	Mus musculus	157-166
23833238-9	2013	To determine whether these effects were due to suppression of IFN-gamma, linezolid-treated animals were given intranasal instillations of rIFN-gamma before challenge with S. pneumoniae.	Linezolid	73-82	interferon gamma	Rattus norvegicus	138-148
23833238-10	2013	This partially reversed the protective effects observed in the linezolid-treated mice, suggesting that the modulatory effects of linezolid are mediated partially by its ability to blunt IFN-gamma production.	Linezolid	63-72	interferon gamma	Mus musculus	186-195
23833238-10	2013	This partially reversed the protective effects observed in the linezolid-treated mice, suggesting that the modulatory effects of linezolid are mediated partially by its ability to blunt IFN-gamma production.	Linezolid	129-138	interferon gamma	Mus musculus	186-195
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	monoamine oxidase A	Homo sapiens	70-75
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	monoamine oxidase B	Homo sapiens	80-85
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	latexin	Homo sapiens	149-152
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	monoamine oxidase A	Homo sapiens	157-168
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	latexin	Homo sapiens	171-174
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	monoamine oxidase B	Homo sapiens	179-184
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	latexin	Homo sapiens	171-174
23532096-6	2013	Compared with untreated and vancomycin-treated rabbits, improved survival of rabbits treated 1.5 hours after infection with linezolid was associated with a significant decrease in bacterial counts, suppressed bacterial production of PVL and Hla, and reduced production of the neutrophil-chemoattractant interleukin 8 in the lungs.	Linezolid	124-133	interleukin-8	Oryctolagus cuniculus	303-316
23021974-1	2013	Linezolid, an oxazolidinone class antibiotic is a reversible and nonselective inhibitor of monoamine oxidase (MAO) enzyme, mainly for MAO-A subtype.	Linezolid	0-9	monoamine oxidase A	Mus musculus	134-139
23529866-26	2013	Linezolid reaches high CSF concentrations; however, more frequent dosing might be required in infants due to their increased elimination.	Linezolid	0-9	colony stimulating factor 2	Homo sapiens	23-26
23428155-1	2013	The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low hERG inhibition.	Linezolid	285-294	ETS transcription factor ERG	Homo sapiens	321-325
23223015-6	2013	The amount of mitochondrial translation products, the p.MT-CO1/succinate dehydrogenase subunit A ratio and the ratio of respiratory complex IV quantity to citrate synthase (CS)-specific activity were significantly lower, after the treatment with linezolid, in cybrids harboring the highly frequent m.3010A allele.	Linezolid	246-255	citrate synthase	Homo sapiens	155-171
23223015-6	2013	The amount of mitochondrial translation products, the p.MT-CO1/succinate dehydrogenase subunit A ratio and the ratio of respiratory complex IV quantity to citrate synthase (CS)-specific activity were significantly lower, after the treatment with linezolid, in cybrids harboring the highly frequent m.3010A allele.	Linezolid	246-255	citrate synthase	Homo sapiens	173-175
23554998-0	2013	Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy.	Linezolid	31-40	23S rRNA methylase	Staphylococcus aureus	18-21
23554998-0	2013	Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy.	Linezolid	140-149	23S rRNA methylase	Staphylococcus aureus	18-21
23554998-0	2013	Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy.	Linezolid	140-149	23S rRNA methylase	Staphylococcus aureus	18-21
23554998-2	2013	Resistance to linezolid due to the cfr gene is described worldwide.	Linezolid	14-23	23S rRNA methylase	Staphylococcus aureus	35-38
23554998-3	2013	The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area.	Linezolid	70-79	23S rRNA methylase	Staphylococcus aureus	57-60
23554998-4	2013	A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates.	Linezolid	38-47	23S rRNA methylase	Staphylococcus aureus	25-28
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P<0.05).	Linezolid	50-59	interleukin 6	Mus musculus	111-115
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P<0.05).	Linezolid	50-59	interferon gamma	Mus musculus	139-148
22371294-1	2012	PURPOSE: To evaluate the usefulness of daptomycin, tigecycline, and linezolid for the treatment of MRSA infection compared with vancomycin in Belgium, the United Kingdom/Ireland, and Spain.	Linezolid	68-77	solute carrier family 9 member A6	Homo sapiens	99-103
21976769-10	2011	All hVISA isolates were susceptible to linezolid, tigecycline, and ceftaroline.	Linezolid	39-48	mitochondrial antiviral signaling protein	Homo sapiens	4-9
24648596-7	2012	In the case of Staphylococcus aureus, repeated observations support the inhibition of production of certain staphylococcal toxins (Panton-Valentine leukocidin, protein A, and alpha- and beta-hemolysin) by linezolid, whereas only solitary reports indicate inhibition (toxic shock syndrome toxin-1, coagulase, autolysins, and enterotoxins A and B) or stimulation (phenol-soluble modulins) of toxin production by linezolid.	Linezolid	205-214	AT695_RS11870	Staphylococcus aureus	175-200
22734900-8	2012	With respect to baseline measurements, linezolid therapy increased both PGP-ir and OXPHOS, which could be considered an initial compensatory toxic-induced response.	Linezolid	39-48	phosphoglycolate phosphatase	Homo sapiens	72-75
22168812-6	2011	RESULTS: Oxacillin, moxifloxacin and linezolid led to the development of a hyper-adhesive phenotype in the fibronectin adhesion assay that was consistent with an increase in fnbA/B transcription.	Linezolid	37-46	fibronectin 1	Homo sapiens	107-118